Our Work
Latham & Watkins Advises Alkermes on Sale of Athlone, Ireland Facility to Novo Nordisk
May 2, 2024
Healthcare & Life Sciences team represents the global biopharmaceutical company.
Alkermes plc (Nasdaq: ALKS) has announced that it has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately US$91 million.
Latham & Watkins advised Alkermes in the transaction with a corporate deal team led by New York partner Aaron Gardner, Boston partner Julie Scallen, and New York counsel Eliot Choy, with associates Oliver Mobasser, Zhao Wang, Austin Wruble, Jake Hummer, and Jihoo Kim.